<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320862">
  <stage>Registered</stage>
  <submitdate>23/11/2009</submitdate>
  <approvaldate>24/11/2009</approvaldate>
  <actrnumber>ACTRN12609001017213</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of a new fish oil based lipid emulsion (SMOFlipid) compared with olive oil based lipid emulsion (Clinoleic) in pre term (&lt;30 weeks) neonates  a randomised controlled trial</studytitle>
    <scientifictitle>Efficacy and safety of a new fish oil based lipid emulsion (SMOFlipid) compared with olive oil based lipid emulsion (Clinoleic) in pre term (&lt;30 weeks) neonates  a randomised controlled trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neonatal nutrtion</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>SMOFlipid intravenous lipid emulsion (soy oil, MCT(medium chain triglycerides), olive oil and fish oil based).
Dose: 1g/kg on day 1 of study, 2g/kg on day2 and 3g/kg on day3 to day 7 of study</interventions>
    <comparator>Clinoleic intravenous lipid emulsion (olive oil and soy oil based) Dose: 1g/kg on day 1 of study, 2g/kg on day2 and 3g/kg on day3 to day 7 of study</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Long Chain-Poly Uunsaturated Fatty Acid (LC-PUFA) levels in plasma and Red cell membrane analysis</outcome>
      <timepoint>Baseline and Day 8 of the study</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma F2-isoprostane level by GC/MS (Gas chrmatography/Mass spectrometry) method</outcome>
      <timepoint>Baseline and Day 8 of the study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1) Preterm neonates (&lt;30 weeks) admitted in the neonatal unit at King Edward Memorial Hospital for Women and 2) Needing Parenteral Nutrition providing &gt; 75% of energy expenditure requirements for at least 7 days</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>7</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1) Blood culture positive sepsis (2)Unconjugated hyperbilirubinemia (requiring exchange transfusion) (3) Metabolic disorders including lactic and/or uncompensated acidosis (4) No parenteral consent (5) Administration of Intravenous lipid infusion prior to study (6) Postnatal age &gt; 7 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>30/11/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>KING EDWARD MEMORIAL HOSPITAL FOR WOMEN</primarysponsorname>
    <primarysponsoraddress>374 BAGOT ROAD
SUBIACO 
WA 60008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Womens and Infant Research Foundation</fundingname>
      <fundingaddress>374 BAGOT ROAD
SUBIACO 
WA 60008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>UNIVERSITY OF WESTERN AUSTRALIA</othercollaboratorname>
      <othercollaboratoraddress>School of Womens and Infant Health 
374 Bagot Road 
Subiaco WA 6008</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Fat emulsions are an essential part of parenteral nutrition (PN) combining a high energy load with an essential fatty acid (EFA) intake.The primary purpose of this study is to test the safety and efficacy of new fish oil based intravenous fat emulsion (SMOFlipid) as compared to traditional olive oil based intravenous fat emulsion (Clinoleic). This study will specifically look at plasma and red cell fatty acid levels particularly Docosahexaenoic acid (DHA) which plays an important role in development and vision of newborn babies and also oxidative strss levels (F2-isoprostanes) before and after the intervention in a randomised controlled trial.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>KING EDWARD MEMORIAL HOSPITAL FOR WOMEN</ethicname>
      <ethicaddress>374 BAGOT ROAD 
SUBIACO 
WA 6008</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GIRISH DESHPANDE</name>
      <address>Department of Neonatal Paediatrics,
Nepean Hospital
Derby St, Kingswood, NSW 2747.</address>
      <phone>+61-8-93402222</phone>
      <fax>+61-8-93401262</fax>
      <email>girish.deshpande@swahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>GIRISH DESHPANDE</name>
      <address>Department of Neonatal Paediatrics,
Nepean Hospital
Derby St, Kingswood, NSW 2747.</address>
      <phone>+61-8-93402222</phone>
      <fax>+61-8-93401262</fax>
      <email>girish.deshpande@swahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>GIRISH DESHPANDE</name>
      <address>Department of Neonatal Paediatrics,
Nepean Hospital
Derby St, Kingswood, NSW 2747.</address>
      <phone>+61-8-93402222</phone>
      <fax>+61-8-93401262</fax>
      <email>girish.deshpande@swahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>